anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Cancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment and reduced survival. Therapeutic strategies for this serious condition are very limited. Growth differentiation factor 15 (GDF-15) is a cytokine that is implicated in cancer cachexia and may represent both a biomarker of cancer cachexia and a potential therapeutic target. Ponsegromab is a potent and selective humanized monoclonal antibody that inhibits GDF-15-mediated signalling. Preclinical and preliminary phase 1 data suggest that ponsegromab-mediated inactivation of circulating GDF-15 may lead to improvement in key characteristics of cachexia. The primary objective of this phase 2 study is to assess the effect of ponsegromab on body weight in patients with cancer, cachexia and elevated GDF-15 concentrations. Secondary objectives include assessing physical activity, physical function, actigraphy, appetite, nausea and vomiting, fatigue and safety. Exploratory objectives include evaluating pharmacokinetics, pharmacodynamics, immunogenicity, lumbar skeletal muscle index and Response Evaluation Criteria in Solid Tumors.
METHODS: Approximately 168 adults with non-small-cell lung, pancreatic or colorectal cancers who have cachexia and elevated GDF-15 concentrations will be randomized in a double-blind, placebo-controlled study (NCT05546476). Participants meeting eligibility criteria will be randomized 1:1:1:1 to one of three dose groups of ponsegromab (100, 200 or 400 mg) or matching placebo administered subcutaneously every 4 weeks for an initial 12-week treatment period. This is followed by optional open-label treatment with ponsegromab of 400 mg administered every 4 weeks for up to 1 year. The primary endpoint is mean change from baseline in body weight at Week 12. A mixed model for repeated measures followed by a Bayesian Emax model will be used for the primary analysis. Secondary endpoints include physical activity, physical function and actigraphy measured by remote digital sensors; patient-reported appetite-related symptoms assessed by Functional Assessment of Anorexia-Cachexia Therapy subscale scores; anorexia/appetite, nausea and vomiting, and fatigue evaluated according to questions from the Cancer-Related Cachexia Symptom Diary; and incidence of adverse events, safety laboratory tests, vital signs and electrocardiogram abnormalities.
PERSPECTIVE: Cancer-related cachexia is an area of significant unmet medical need. This study will support the clinical development of ponsegromab as a novel inhibitor of GDF-15, which may ameliorate key pathologies of cancer cachexia to improve patient symptoms, functionality and quality of life.
TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT05546476.
The present invention relates to a polysaccharide fraction derived from barley leaves which has immunity function promotion activity and use thereof. More specifically, the polysaccharide fraction derived from barley leaves is prepared by: (a) a step of processing the barley leaves with a pectin hydrolysis enzyme; and (b) extracting the hydrolyzed barley leaves with hot water. The polysaccharide fraction derived from barley leaves comprises 65-85 wt% of neutral sugar and 5-30 wt% of uronic acid with respect to the total polysaccharide fraction. The polysaccharide fraction has excellent immunity enhancing activity and cancer transition inhibiting activity. According to the present invention, the barley leaf polysaccharide fraction has not only an excellent effect of enhancing the congenital immune system and adaptive immune system but also cancer transition inhibiting activity. Therefore, the barley leaf polysaccharide fraction can be effectively used to manufacture a competent composition for immunity enhancing food and an immunity enhancing medical product and to develop a cancer treatment agent.
M-protein related cardiac disease aged 18 and above (at least one of the following criteria is met): (1) Systemic amyloidosis of the affected heart; (2) Presence of M component and presence of arrhythmia, cardiac enzyme abnormalities, cardiac function abnormalities, and exclusion of other diagnosable cardiac diseases. It is expected to include 40 patients with M-protein related cardiac disease. The treatment medication for enrolled patients must comply with the treatment regimen of Daratumumab + Bortezomib + Dexamethasone. All patients were given Dapagliflozin 10mg/day at the beginning of treatment (creatinine clearance rate greater than 20ml/min).
PURPOSE: A composition containing L1CAM expression or activation inhibitor is provided to suppress growth, transition, and infiltration of gallbladder cancer. CONSTITUTION: A pharmaceutical composition for suppressing growth or transition of gallbladder cancer contains L1CAM(L1 cell adhesion molecule) expression or activation inhibitor as an active ingredient. The L1CAM has an amino acid sequence of sequence number 1. The L1CAM expression inhibitor is antisense nucleotide, siRNA, or shRNA of L1CAM gene. The L1CAM activation inhibitor is a compound, peptide, peptide mimetics, aptamer, or antibody of L1CAM. A method for selecting the inhibitor comprises: a step of treating a test material to L1CAM expression cell line; a step of measuring L1CAM expression level in the cell line; and a step of selecting the test material.
<P>PROBLEM TO BE SOLVED: To obtain a more effective functional activator of dendritic cell and to provide a method for producing dendritic cells having an activated function.  <P>SOLUTION: The functional activator of dendritic cell comprises at least one branched-chain amino acid selected from isoleucine, leucine and valine as an active ingredient. The method for producing dendritic cells having an activated function comprises culturing dendritic cells or their precursor cells in a medium containing the activator. The dendritic cells having an activated function are provided by the method. The prophylactic or therapeutic agent comprises the cells.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
OBJECTIVE: This epidemiological study estimated the lifetime prevalence of chronic physical illness (i.e., an illness that lasted or was expected to last ≥6 months) and 6-month prevalence of mental disorder and multimorbidity (i.e., ≥1 physical illness and ≥1 mental disorder) in youth. Associations between physical illness and mental disorder were quantified, including the number of illnesses. Secondary objectives examined factors associated with mental disorder, after controlling for physical illness.
METHODS: Data come from 10,303 youth aged 4-17 years in the 2014 Ontario Child Health Study (OCHS). Physical illness was measured using a list of chronic conditions developed by Statistics Canada. Mental disorders were measured using the OCHS Emotional Behavioural Scales. The Health Utility Index Mark III assessed overall functional health.
RESULTS: Weighted prevalence estimates showed 550,090 (27.8%) youth had physical illness, 291,986 (14.8%) had mental disorder, and 108,435 (5.4%) had multimorbidity. Physical illness was not associated with mental disorder. However, youth with 2 physical illnesses, as compared to no physical illnesses, had increased odds of having any mental (OR = 1.75 [1.08, 2.85]), mood (OR = 2.50 [1.39, 4.48]) and anxiety disorders (OR = 2.40 [1.33, 4.31]). Mean functional health scores demonstrated a dose-response association across health status categories, with the highest scores among healthy youth and the lowest scores among multimorbid youth (all p < .05).
CONCLUSION: Chronic physical illness and mental disorders are prevalent in youth. Youths with 2 physical illnesses have a higher likelihood of mental disorders. Higher functional health scores protected against all mental disorders. Mental health interventions for youth should promote strong overall functional health.
PLAIN LANGUAGE SUMMARY TITLE: Physical-Mental Multimorbidity in Ontario Youth.
Crohn's disease (CD) is a chronic inflammatory disease of the digestive tract. The incidence of pediatric CD is increasing and is currently 2.5-11.4 per 100000 world-wide. Notably, approximately 25% of children with CD develop stricturing CD (SCD) that requires intervention. Symptomatic stricturing diseases refractory to pharmacological management frequently require non-pharmacological interventions. Non-pharmacological therapeutic strategies include endoscopic balloon dilatation, stricturoplasty, and surgical resection of the strictured segment. However, strictures tend to recur postoperatively regardless of treatment modality. The lifetime risk of surgery in patients with childhood SCD remains at 50%-90%. Thus, new and emerging strategies, advanced diagnostic tools, and minimally invasive approaches are under investigation to improve the outcomes and overall quality of life of pediatric patients with SCD.
PURPOSE: A celivarone or formula accdeptable salt thereof is provided to prevent cardiocascular diseases. CONSTITUTION: A compound selected from celivarone and pharmaceutically acceptable salt thereof is used for manufacturing a drug for preventing cardiovascular diseases. The compound is administered by oral pathway. A daily dose of the compound is 50-300 mg. The compound is taken during eating. The compound is 2-butyl-3-[4[3-(dibutyl amino)]propyl]benzoyl]-1-benzofuran-5-carboxylic acid isopropyl ester fumarate.
Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
1,244,207. Radiopaque compositions. PHARMACIA A.B. 15 Nov., 1968 [16 Nov., 1967], No. 54274/68. Addition to 1,204,862. Heading A5B. [Also in Division C3] Water soluble linear or branched polymers, which may be used as solutions or with physiologically acceptable carriers in the X-ray visualisalion of body cavites, have M.W. 1700-5000 and have alternating iodobenzene groups of formula: (or physiologically acceptable salts thereof) and intermediate straight or branched aliphatic C 3-30  hydroxyl containing bridges, optionally interrupted by one or more oxygen bridges. The polymer contains at least 3 idobenzene groups (I). The polymer is obtainable by reacting a 3,5-bifunctional 2,4,6-triiodobenzoic acid derivative with an aliphatic bridge former which contains one or more OH groups or is capable of forming one or more OH groups in the polymerisation process. Examples of suitable bridge formers are bis(2,3-epoxypropyl)-ether, 1,2-ethanediol diglycidyl ether, 1,4-butanediol diglycidyl ether or 1,3-glycerol diglycidyl ether. The iodobenzoic acid may have amino or amido substituents in the 3- and 5-positions as discribed in the parent Specification No. 1,204,862.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A 24-week, randomized, double-blind, placebo-controlled clinical trial of Vimizim was conducted in 176 patients with MPS IVA, ages 5 to 57 years old. Approximately half of the patients (49%) were male. Of the 176 patients, 65% were White, 23% Asian, 3% Black, and 10% Other race. The majority of patients (78%) were non-Hispanic. Patients were randomized to three treatment groups: Vimizim 2 mg/kg once per week (n=58), Vimizim 2 mg/kg once every other week (n=59), or placebo (n=59). All patients were treated with antihistamines prior to each infusion.

Table 1 summarizes the most common adverse reactions that occurred in the placebo-controlled trial with an incidence of ≥ 10% in patients treated with Vimizim 2 mg/kg once per week and with a higher incidence than in the placebo-treated patients. 

Table 1: Adverse Reactions That Occurred in the Placebo-Controlled Trial in At Least 10% of Patients in the Vimizim 2 mg/kg Once Per Week Group and with a Higher Incidence than in the Placebo Group

Extension Trial

An open-label extension trial was conducted in 173 patients who completed the placebo-controlled trial [see Clinical Studies (14)]. No new adverse reactions were reported.
All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years and/or ≥ 40 kgs will receive a voxelotor dose of 1500 mg QD. Participants aged \< 12 years and \< 40 kgs will receive weight based dosing of voxelotor. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source.
During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
The present invention relates to functional instant millet gruel which is characterized in that millet and a small amount of corn are used as main materials to add functional components, such as lotus leaves, tuckahoe, Chinese wolfberries, Chinese dates, etc.; mixed materials are extruded, bulked and formed to obtain bulked raw materials after mixed. The bulked raw materials are made into the functional instant millet gruel by adding lotus powder as a natural thickening agent and by adding auxiliary materials, such as peanuts, sunflower seeds, sesames, etc., and flavoring packets containing white granulated sugar, small fresh vegetables, etc. The present invention can be made into instant millet gruel having various flavors and different functions according to the differences among functional components added and auxiliary materials added. The present invention has the advantages of raw material utilization value enhancement and resource added value enhancement. The instant millet gruel developed by the present invention has the advantages of abundant nutrients and high functionality. The instant millet gruel overcomes the disadvantage of no viscosity of bulked instant gruel after rehydrated. The instant millet gruel maintains the natural shape and the natural flavor of a millet gruel food. The present invention improves the development level of the millet gruel food and opens up a new path for the further development of other coarse grain nutrient instant foods.
PROBLEM TO BE SOLVED: To provide the subject new compound useful as a selective anti- Helicobacter pyrori agent free from antibacterial activity against bacteria other than Helicobacter pyrori. SOLUTION: The objective compound is a carboxyhydroxamide derivative expressed by the formula I (X is O or S; Y is a halogen, a 1-3C alkyl, etc.; (n) is an integer of 1-4; R<1> is H, a halogen, a 1-3C alkyl, etc.) or it salt, hydrate or solvate, e.g. benzofuran-2-carboxyhydroxamide. The compound of the formula I can be produced by converting benzothiophene-2-carboxylic acid of the formula II into the acid chloride of the formula III with phosphoryl chloride, etc., in an organic solvent such as benzene sing zinc chloride, etc., as a catalyst and adding excess base such as hydroxylamine or sodium hydroxide to the acid chloride in a solvent to effect the reaction with hydroxylamine.
Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
PURPOSE:To make a work with high actuality possible by changing the amt. of deformation and the amt. of counterforce during processing in a processing work of a display article on a graphic display screen. CONSTITUTION:An arithmetic processor 13 controls automatically the amt. of processing deformation of an article 11 to be processed by a processing tool 12 on a display screen and the amt. of counterforce at that time by the kind of a work commanding tool 2 or setting from an inputting apparatus 30. An operator can operate, thereby processing of the article 11 to be processed displayed with an optimum actuality is enabled.
A method of mRNA production for use in transfection is provided, that involves in vitro transcription of PCR generated templates with specially designed primers, followed by polyA addition, to produce a construct containing 3′ and 5′ untranslated sequence (“UTR”), a 5′ cap and/or Internal Ribosome Entry Site (IRES), the gene to be expressed, and a polyA tail, typically  50 - 2000  bases in length. This RNA can efficiently transfect different kinds of cells. This approach results in increased efficiency (fidelity and productivity) of mRNA synthesis and is less time consuming because it does not require cloning, and also consequently eliminates the unwanted errors and effects related to RNA made on DNA templates obtained with cloning techniques. The results of transfection of RNAs demonstrate that RNA transfection can be very effective in cells that are exceedingly difficult to transfect efficiently with DNA constructs. Further, the levels of gene expression following mRNA transfection are consistent from cell to cell in an experiment and these levels can be controlled over a wide range simply by changing the amount of mRNA that is transfected, and without obvious cytotoxic effects due to the levels of RNA per se. Due to high efficiency the cells can be simultaneously transfected with multiple genetic constructs. The method can be used to deliver genes into cells not- or only poorly transfectable for DNA, in vitro and in vivo.
A drug-dispensing dressing for administering a fluid containing an antifungal agent to a fungus infected nail on a toe or a finger. In a preferred embodiment, the dressing includes: (a) a reservoir comprising a substantially flat, fluid-absorbant pad having a first hole therein; and (b) an elongate strip of a fluid impermeable material having a central portion with a second hole therein. The elongate strip has a skin-facing surface coated with a layer of adhesive. The skin-facing surface of the central portion of the strip is affixed to the fluid-absorbant pad with the second hole overlying the first hole. The dressing is affixed to a toe and the reservoir, which is rechargeable, is charged with a fluid antifungal agent introduced dropwise or injected through the hole where the fluid is absorbed and disbursed by the pad and slowly released to the underlying nail. The dressing may further include a removable, preferably elastic, barrier layer disposed over the holes. In another embodiment, the reservoir is attached to the inner surface of an elastic tube to underlie a hole in the tube. The tubular dressing is stretched and placed over the affected toe with the reservoir overlying the infected nail and the antifungal agent introduced into the reservoir via the hole.
A water insoluble, physiologically harmless compsn. comprises boiled and compact dried starch (I). (I) may opt. contain a polyvalent aliphatic alcohol e.g. glycerol or sorbitol to improve elasticity and flexibility and organic flavourants to improve strength and water insolubility. (I) is prepd. by boiling starch and drying the paste as a continuous mass e.g. in the form of a block or a film. (I) is esp. maize starch. (I) may be used to form water insoluble, swellable coatings on everyday articles or on food and medicine, as microcapsules, containers and carriers for e.g. enzymes, vitamins, medicines.
This study will be carried out as a pre-test - post-test randomized controlled experimental study. The population of the research consists of female patients between the ages of 45-55 who are registered to a family health center located in a provincial center in the north of Turkey. Women who are in the perimenopausal period and meet the inclusion criteria according to the Staging of Reproductive Aging in Women (STRAW) criteria will be included in the study. The random.org program will be used to unbiasedly assign 60 women who meet the research criteria to the experimental and control groups.

The menopause adaptation program will be applied to the intervention regimen. This program, which will be applied to the experimental group, was prepared based on the Meleisin Transition theory. Since women's menopause is a transition process, the transition theory was preferred. Within the scope of the program, the experimental group will be given online menopause health education for the first 6 weeks and baduanjin exercise will be taught. For the next 8 weeks, individuals will be asked to practice the baduanjin exercise 3 times a week. Online consultation will be provided during this period.

The study will be completed in 14 weeks in total. No intervention will be applied to the control group. The study will be terminated after the post-test data is collected. Data will be collected using the Introductory Information Form, the Attitudes Towards Menopause Scale (MITÖ, Spirituality Index of Well-Being Scale).
In COVID-19 pandemic, it is of critical importance to identify a rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, control, and stop the spread of SARS-CoV-2. The 2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative, membrane-based immunoassay for the detection of Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies to SARS-CoV-2in whole blood, serum or plasma specimen. This test consists of two components, an IgG component and an IgM component. In the IgG component, anti-human IgG is coated in IgG test line region. During testing, the specimen reacts with 2019-nCoV antigen-coated particles in the test cassette. The mixture then migrates upward on the membrane chromatographically by capillary action and reacts with the anti-human IgG in IgG test line region, if the specimen contains IgG antibodies to SARS-CoV-2. The study aims to validate in a real life study a self diagnostic assay for SARS-CoV-2 with the advantages of high speed, simple operation and low cost, and overcomes the shortcomings of the existing molecular detection methods. Clinical specimens from patients who were suspected of being infected with 2019-nCoV will be used to evaluate the performance of the assay. In parallel, we will also use molecular assays for the detection of the presence of the viral RNA from nasopharyngeal swabs since Polymerase Chain Reaction is currently the gold standard.